Characterization of the Signaling Capacities of the Novel gp130-like Cytokine Receptor
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The gp130-like receptor (GPL) is a recently cloned member of the family of type I cytokine receptors. The name reflects its close relationship to gp130, the common receptor subunit of the interleukin (IL)-6-type cytokines. Indeed, the recently proposed ligand for GPL, IL-31, is closely related to the IL-6-type cytokines oncostatin M, leukemia inhibitory factor, and cardiotrophin-1. The second signal transducing receptor for IL-31 seems to be the oncostatin M receptor beta (OSMRbeta). The present study characterizes in depth the molecular mechanisms underlying GPL-mediated signal transduction. GPL is a strong activator of STAT3 and STAT5, whereas STAT1 is only marginally tyrosine-phosphorylated. We identify tyrosine residues 652 and 721 in the cytoplasmic region of the longest isoform of GPL (GPL(745)) as the major STAT5- and STAT3-activating sites, respectively. Additionally, we demonstrate Jak1 binding to GPL and its activation in heteromeric complexes with the OSMRbeta but also in a homomeric receptor complex. Most interesting, unlike OSMRbeta and gp130, GPL is insufficient to mediate ERK1/2 phosphorylation. We propose that this is due to a lack of recruitment of the tyrosine phosphatase SHP-2 or the adaptor protein Shc to the cytoplasmic domain of GPL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272
Self-citationStahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., & Yancopoulos, G. D. (1995) · Science · doi:10.1126/science.7871433 · Cited by 979
Lütticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., Harpur, A. G., Wilks, A. F., Yasukawa, K., Taga, T., et al. (1994) · Science · doi:10.1126/science.8272872 · Cited by 814
Self-citationRaf meets Ras: completing the framework of a signal transduction pathway
Avruch, J., Zhang, X.-F., & Kyriakis, J. M. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90005-1 · Cited by 577
Nakajima, K., Yamanaka, Y., Nakae, K., Kojima, H., Ichiba, M., Kiuchi, N., Kitaoka, T., Fukada, T., Hibi, M., & Hirano, T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00734.x · Cited by 565
Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras.
Bennett, A. M., Tang, T. L., Sugimoto, S., Walsh, C. T., & Neel, B. G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7335 · Cited by 397
SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130
Lehmann, U., Schmitz, J., Weissenbach, M., Sobota, R. M., Hörtner, M., Friederichs, K., Behrmann, I., Tsiaris, W., Sasaki, A., Schneider-Mergener, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210552200 · Cited by 236
Self-citationSCHAPER, F., GENDO, C., ECK, M., SCHMITZ, J., GRIMM, C., ANHUF, D., KERR, I. M., & HEINRICH, P. C. (1998) · Biochemical Journal · doi:10.1042/bj3350557 · Cited by 178
Self-citationHermanns, H. M., Radtke, S., Haan, C., Schmitz-Van de Leur, H., Tavernier, J., Heinrich, P. C., & Behrmann, I. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6651 · Cited by 71
Self-citation
Cited by
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
IL-31 regulates differentiation and filaggrin expression in human organotypic skin models
Cornelissen, C., Marquardt, Y., Czaja, K., Wenzel, J., Frank, J., Lüscher-Firzlaff, J., Lüscher, B., & Baron, J. M. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.10.042 · Cited by 290
Structures and biological functions of IL-31 and IL-31 receptors
Zhang, Q., Putheti, P., Zhou, Q., Liu, Q., & Gao, W. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.08.003 · Cited by 287
Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology
Hermanns, H. M. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.006 · Cited by 263
“did not find a recruitment site to either the IL31RA or OSMRb [142].”
BackgroundSelf-citationEmerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis
Furue, M., Yamamura, K., Kido‐Nakahara, M., Nakahara, T., & Fukui, Y. (2018) · Allergy · doi:10.1111/all.13239 · Cited by 240
Signaling by IL-31 and functional consequences
Cornelissen, C., Lüscher-Firzlaff, J., Baron, J. M., & Lüscher, B. (2012) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.07.006 · Cited by 207
IL-31 Expression by Inflammatory Cells is Preferentially Elevated in Atopic Dermatitis
Hofbauer, G., Nobbe, S., Dziunycz, P., Mühleisen, B., Bilsborough, J., Dillon, Sr., & French, L. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1191 · Cited by 158
Interleukin‐31 and interleukin‐31 receptor: New therapeutic targets for atopic dermatitis
Nakashima, C., Otsuka, A., & Kabashima, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13533 · Cited by 154
Klein, C., Medina, E., Sander, L., Dierssen, U., Roskams, T., Mueller, W., Trautwein, C., & Goldmann, O. (2007) · The Journal of Infectious Diseases · doi:10.1086/520090 · Cited by 11
Metadata
- Authors
- Dreuw, A., Radtke, S., Pflanz, S., Lippok, B. E., Heinrich, P. C., & Hermanns, H. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-08
- Volume
- 279
- Issue
- 34
- Pages
- 36112-36120
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2020199484
- Cited by
- 90
- References
- 9
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.